FDA panel says Lilly imaging agent not yet ready for market
This article was originally published in Scrip
Executive Summary
A US FDA advisory panel 20 January said Lilly's non-therapeutic radiopharmaceutical Amyvid (florbetapir F 18) is not ready for use with positron emission tomography (PET) to rule out the presence of beta-amyloid in the brain, but left open the possibility of an approval if certain criteria are met.